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Abstract 
Introduction: Factor VIII inhibitor development is currently the most serious 
complication of the treatment of Haemophilia A.  Differences in manufacturing and the 
molecular structure of brands of recombinant factor VIII have led to speculation that 
concentrates may differ in immunogenicity1-4.  This has led to a regulatory focus on the 
immunogenicity of the factor VIII concentrates both before and after licensure.  Aim: 
To collect post-marketing data on >100 UK previously untreated patients (PUPs) 
treated exclusively with ReFacto AF until at least 50 EDs.  Methods: The United 
Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) National Haemophilia 
Database (NHD) identified a consecutive cohort of patients with severe haemophilia A 
(<0.01 IU/l) whose first treatment was with ReFacto AF and collated a report of 
inhibitor incidence and inhibitor risk-factors.  Results: 103 boys reached 50 EDs within 
the study period; 68 (66.0%) did not develop an inhibitor and 35 (34.0% [95% CI 24.7 
– 43.3%]) did, of which 15 (14.6% [95% CI 7.6 – 21.5%]) were high titre.  Inhibitors 
arose after a median (interquartile range) 11 (7-16) EDs.  Inhibitors were significantly 
associated with high risk mutations and non-significantly associated with non-white 
ethnicity.  Conclusion: Inhibitor incidence in a single country population of ReFacto 
AF PUPs was similar to that previously described.  Low and high titre inhibitors were 
detected after a similar number of EDs, contrasting with previous data, probably 
reflecting standardised inhibitor monitoring within the UK. 
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Introduction 
Pivotal studies in previously untreated patients (PUP) studies are open, non-
comparative and, with a relatively small sample-size, have very limited statistical 
power.  They are therefore unsuitable for the detection of small differences in 
immunogenicity5-7.  The clinical trial setting and strict entry criteria also limit the extent 
to which the results of such studies may be extrapolated to the general patient 
population.  For this reason, post-authorisation surveillance has assumed increasing 
importance in assessing less frequent side-effects and subtler differences in 
comparative immunogenicity of factor VIII products and in providing a real-world 
perspective.  Indeed, some product differences have become apparent only after 
follow-up of 400 or more PUPs over periods of ten years or more7-9.   
The UK National Haemophilia Database (NHD) registers and monitors all patients with 
severe haemophilia A as part of a prospective program of pharmacovigilance and 
ongoing investigation into the risk factors and potential prevention of factor VIII 
inhibitor development9-12.  
Following market authorisation of ReFacto AF (Pfizer, Walton Oaks, Tadworth, UK) in 
2009, the European Medicine Agency requested that Pfizer conduct a post-
authorisation safety surveillance registry of ReFacto AF in PUPS in usual care 
settings.  The UKHCDO Data Collection was supplemental to the Pfizer registry data 
and enabled Pfizer to secure the requisite numbers for ReFacto AF.  This study was to 
include at least 100 consecutive UK patients treated exclusively with ReFacto AF for at 
least 50 exposure days (ED).  In 2010, the UK National Procurement Exercise 
awarded 47% of the contract for supply of factor VIII to Pfizer Ltd (ReFacto AF).  
Consequently, 34% of UK PUPs were allocated to ReFacto AF on a contractual basis 
from 2010.  
 
Methods 
The United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) NHD was 
used to identify consecutive children with severe haemophilia A (<0.01 IU/l) whose first 
treatment was with ReFacto AF.  PUPs were selected to be treated with ReFacto AF 
or other products non-randomly to achieve contractual volume requirements.  Most 
large Haemophilia Centres allocate product brand to PUPs on a rotational basis but 
this is not universal.  Patients diagnosed outside the UK were excluded because their 
previous treatment history was unknown.  
UKHCDO guidelines recommend inhibitor testing of PUPS every third exposure day 
until 20 EDs and then every 5th ED until 50 EDs10.  Inhibitor tests were conducted 
locally using either a Bethesda or Nijmegen assay or a pharmacokinetic test.   All 
laboratories participate in a national quality control exercise and are inspected and 
accredited by Clinical Pathology Accreditation (CPA).  
Adverse events including new factor VIII inhibitors are reported to NHD electronically 
when they occur.  Inhibitor reports require a second confirmatory test.  The continued 
presence of an inhibitor is indicated in each quarterly report from Haemophilia Centres 
to the NHD.  Each inhibitor report to the NHD includes details of the laboratory method 
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used and the normal range for the local laboratory.  Some low-level inhibitors (below 
the limit of detection of the Bethesda assay) are diagnosed based on a reduced half-
life and/or recovery, in keeping with UKHCDO guidelines10.  High-titre inhibitors are 
defined as those with a recorded peak inhibitor titre ≥ 5 Bethesda Units (BU), whereas 
low-titre inhibitors are those where the recorded peak inhibitor titre is < 5 BU.  EMA 
defined thresholds for inhibitor titre were utilised in this study, with titres ≥5 BU 
considered high titre and titres ≥0.6 and <5 BU considered lower titre13.  A sub-
analysis including UKHCDO pharmacokinetic definitions is described.  Transient 
inhibitors were identified by examining the number of calendar quarters in which each 
inhibitor was reported to be present, and defined as those which were reported in just 
one quarter.  
The number of factor VIII EDs prior to first inhibitor detection was provided in the 
corresponding adverse event report.  For patients who did not develop an inhibitor, the 
number of EDs to date was estimated by dividing their total exposure to ReFacto AF 
by the mean units used per exposure day in 50 inhibitor-free UK RODIN patients, as 
previously described9.  
Clinical and demographic data were extracted from the NHD, or requested from UK 
Haemophilia Centres.  Age at first treatment is estimated as the mid-point of the 
quarter of first treatment, or at the mid-point of date of birth and the end of the quarter 
of first treatment.  Family history was defined as any confirmed history of haemophilia 
and/or factor VIII inhibitor development in a first or second degree relative.  Ethnicity is 
categorised as white or non-white.  FVIII mutations are categorized as high risk (large 
deletions, nonsense mutations, intron 1 and 22 inversions), low risk (small deletions 
and insertions, missense mutations, splice site mutations), awaiting categorisation or 
unknown (no mutation detected or testing status unknown).  Intron 22 inversions were 
included in the high-risk mutation category and also analysed separately, given 
previous reports suggesting that it was associated with an intermediate risk of inhibitor 
development.  
 
Statistics 
Descriptive statistical analysis includes medians, interquartile ranges (IQR) and 
Kaplan-Meier (K-M) estimates of probabilities of inhibitor development within fifty 
exposure days (EDs), P(t≤50), with 95% confidence intervals (CI).  Time to inhibitor 
development, measured in EDs, is illustrated using K-M curves.  Differences in K-M 
curves are tested using the log rank test.  
 
Results 
Of the 113 eligible patients identified between 2010 and 2017, 103 have either 
progressed to 50 EDs without developing an inhibitor (n=68, 66.0%) or developed a 
confirmed inhibitor prior to 51 EDs (n=35, P(t≤50)=0.33, [95% CI 0.25 – 0.43]) (Figure 
1).  These inhibitors were first detected between 2010 and 2017.  
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There was one confirmed report of a transient inhibitor, and for a further four patients, 
inhibitors were reported only once, and thus also considered transient.  A further seven 
non-inhibitor patients are yet to reach 50 EDs, and three non-inhibitor patients 
switched products prior to 51 EDs. 
Inhibitors prior to 51 EDs were identified after a median (iqr) 11 (7-16) EDs.  High-titre 
inhibitors arose in 15 (P(t≤50)=0.16, [95% CI 0.10 – 0.25]) patients before 51 EDs, 
arising after a median of 11 (8-16) EDs.  Low-titre inhibitors were reported in 20 
(P(t≤50)=0.20, [95% CI 0.14 – 0.30]) patients before 51 EDs, arising at a median of 11 
(6.25-15) EDs. 
The seven non-switching inhibitor-free patients who have not reached 50 EDs in this 
study had been followed up for an estimated median (iqr) 7.5 (4.5-10.5) calendar 
months by 31st December 2017, and 4.1 (1.6-12.2) exposure days.  They were first 
treated in 2016 or 2017.  The three patients who switched products were initially 
treated with up to 1250 units of ReFacto AF as PUPs before they switched to either 
Advate (n=2), after 1 and 2 EDs, or to Nuwiq, after 2 EDs.  These ten patients with 
incomplete follow-up are included in the Kaplan-Meier analysis (Figure 2) prior to 
censoring at their most recent exposure to ReFacto AF, or the point at which they 
changed products. 
Additionally, five patients were reported to have been given up to 3000 units of other 
products (3 Advate, 1 Kogenate, 1 Helixate Nexgen), presumably in error.  All were 
treated previously and subsequently exclusively with ReFacto AF.  Rather than 
excluding them or censoring their data, they have been treated as ‘protocol variations’ 
and their full follow-up has been included in the analysis.  
Most patients (n=96) (Table 1) were of white ethnicity.  Non-white patients were more 
likely to develop inhibitors (6/12 (P(t≤50)=0.49, [95% CI 0.26 – 0.79])) than white 
patients (29/91 (P(t≤50)=0.31, [95% CI 0.23 – 0.42])) before 51 EDs (p=0.30) and this 
difference was more marked for high titre inhibitors (3/12 (P(t≤50)=0.30, [95% CI 0.10 
– 0.68])) and 12/91 (P(t≤50)=0.15, [95% CI 0.09 – 0.24])), respectively (p=0.30).  
FVIII mutation was reported for 105 patients.  Most had a high-risk mutation (n=79), 
whilst 26 had a low risk mutation.  The high-risk mutation patient group developed 
significantly more inhibitors before 51 EDs (29/71 (P(t≤50)=0.40, [95% CI 0.30 – 
0.52])) than the low risk mutation patient group (4/25 (P(t≤50)=0.16, [95% CI 0.06 – 
0.37]))  (p=0.03).  Figure 3 shows time to inhibitor detection by mutation group.  The 
proportion of patients with intron 22 inversions who developed inhibitors prior to 51 
EDs (23/54 (P(t≤50)=0.42, [95% CI 0.30 – 0.56])) was greater than that for the other 
‘high-risk’ mutations (6/17 (P(t≤50)=0.35, [95% CI 0.17 – 0.61])).  This difference was 
not statistically significant (p=0.55).  
A family history of haemophilia was reported in 62 patients, of whom thirteen had a 
family history of inhibitors.  Patients without a family history of haemophilia were 
significantly more likely to develop an inhibitor prior to 51 EDs than those with a family 
history of haemophilia (p=0.04).  Patients with a family history of inhibitors were 
significantly more likely to develop a high titre inhibitor prior to 51 EDs than those 
without a family history of inhibitors (p=0.01).  
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Excluding inhibitors, there were four reported adverse events (intracranial 
haemorrhage, rash, poor efficacy, and post-operative bleed following insertion of a 
central line device).  The patient with the post-operative bleed had an inhibitor 
detected one month earlier, after 14 EDs.  The patient with poor efficacy had been 
treated for intracranial haemorrhage, and was suspected to have an inhibitor due to 
the increased dosing required to maintain levels.  However, no inhibitor was detectable 
on testing, and the patient is therefore coded as inhibitor-free after 50 EDs in this 
report.  A sensitivity analysis was performed recoding this patient as a pre-51 EDs 
inhibitor case (as it meets the UKHCDO criteria), in which the statistical association 
between family history of haemophilia A and inhibitors lost significance.  The outcomes 
of the remaining statistical tests described above were not affected by this 
reclassification.   
A further sensitivity analysis was performed to investigate the effect of the ‘protocol 
variations’ described above in which five patients had been administered small 
amounts of other factor VIII products.  When these patients were excluded, the 
association between high-risk mutations and inhibitors prior to 51 EDs lost statistical 
significance, as did the association with family history of haemophilia A.  The 
outcomes of the other statistical tests were unaffected. 
Follow-up of patients who were inhibitor-free after fifty EDs (n=68) was available for a 
median (iqr) 431 (257-816) days. Inhibitors were detected after fifty EDs in two of 
these patients, after 52 and 160 EDs. 
 
Discussion  
This report describes the occurrence of inhibitors in a consecutive cohort of PUPs 
whose first treatment was with ReFacto AF.  The incidence of inhibitors observed is 
comparable with previous published reports of PUP studies7,8,14,15.  The cumulative 
probability of inhibitor development over time is shown in a Kaplan-Meier plot (Figure 
1).  The wide confidence intervals shown illustrate the degree of uncertainty around 
estimates of immunogenicity of factor VIII products, using samples which are typically 
around this size.  Were one to attempt a comparative trial, a much larger sample would 
be required to demonstrate a difference in immunogenicity. 
Approximately one third of of all UK PUPs who started treatment since the end of 2009 
are included in the cohort.  Patients were non-randomly selected to use  ReFacto AF 
to fulfil national procurement volume committments.  The distribution of inhibitor risk 
factors such as ethnicity, F8 genotype and family history of inhibitors appears 
representative and is very similar to that previously reported for the whole UK PUP 
cohort treated during the period 2000-2011 and using all available products9.  There is 
therefore no evidence of  systematic bias in allocating patients to ReFacto AF. 
As expected, subjects with high risk genotypes had significantly more inhibitors.  The 
association between high risk genotypes and high titre inhibitors did not reach 
statistical significance, possibly because of the small numbers of patients analysed.   
High- and low-titre inhibitors were detected after similar  median EDs (11 in both 
groups).  In the past, low titre inhibitors were thought to tend to arise later than high-
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titre inhibitors.  Our results suggest that historically later detection of low-titre inhibitors 
may be attributable to a sampling artefact, and that low-titre inhibitors may be detected 
earlier when patients are tested more frequently, as has become current clinical 
practice.  
In conclusion, we report that in a consecutive cohort of PUPs treated with ReFacto AF 
in the UK the proportion developing inhibitors was similar to previous PUP studies of 
ReFacto AF and comparable with PUP studies of other recombinant factor VIII 
concentrates.  The confidence intervals around these estimates are wide, however, 
indicating that althought there was no evidence of increased immunogenicity 
associated with ReFacto AF, A formal comparison of the immunogenicity of factor VIII 
concentrates would require a much larger sample. 
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Table 1: Time to inhibitor by clinical and demographic characteristics 
 
Recruited	
(N=113)*
Completed	
(N=103)
Age	at	first	exposure	to	factor	VIII	
(months),	median	(interquartile	range)
8	(2-13) 8	(4-13)
Ethnicity n n n (probability) n (probability) n (probability)
White 96 91 62 (0.69) 29 (0.31) 12 (0.15)
Non-white 17 12 6 (0.51) 6 (0.49) 3 (0.30)
Genotype n n n (probability) n (probability) n (probability)
High	risk 79 71 42 (0.60) 29 (0.40) 13 (0.21)
Low	risk 26 25 21 (0.84) 4 (0.16) 1 (0.05)
Not	known 8 7 5 (0.71) 2 (0.29) 1 (0.14)
Family	history	of	Haemophilia	A n n n (probability) n (probability) n (probability)
Yes 62 57 42 (0.74) 15 (0.26) 7 (0.13)
No 51 46 26 (0.57) 20 (0.43) 8 (0.21)
Family	history	of	inhibitor n n n (probability) n (probability) n (probability)
Yes 13 12 8 (0.67) 4 (0.33) 4 (0.33)
No 49 45 34 (0.76) 11 (0.24) 3 (0.07)
Not	applicable 51 46 26 (0.57) 20 (0.43) 8 (0.21)
*Includes	patients	who	switched	prior	to	50	exposure	days	(n=3)	and	non-inhibitor	patients	yet	to	reach	50	exposure	days	(n=7)
No	inhibitor	prior	to	
51st	exposure	day	
(n=68)
Inhibitors	prior	to	
51st	exposure	day	
(n=35)
High	titre	inhibitors	
prior	to	51st	exposure	
day	(n=15)
8	(2-13) 10	(6-13) 11	(8-16)
		
	
	
	
	
	
	
Eligible (n=113) 
Completed follow-up (n=103) 
Switched to alternative FVIII 
products prior to 50 exposure days 
(n=3) 
Did not reach 50 exposure days 
within study period (n=7) 
Inhibitor-free after 50 
exposure days (n=68) 
Confirmed high titre ≥5 BU 
(n=15) 
 
Developed inhibitor 
prior to 50 exposure 
days (n=35) 
Confirmed low titre 0.6-5 BU 
(n=20) 
Figure	2	-	Time	to	inhibitor	detection	
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Figure	3	-	Time	to	inhibitor	detection	by	genotype	
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